Drug General Information (ID: DDIB8T4P1J)
  Drug Name Metolazone Drug Info Chloral hydrate Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Anxiolytics/Sedatives/Hypnotics
  Structure

 Mechanism of Metolazone-Chloral hydrate Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Metolazone Chloral hydrate
      Mechanism 1 Antihypertensive agent Antihypertensive agent
      Key Mechanism Factor 1
Factor Name Hypotensive effects
Factor Description Hypotension is a blood pressure reading below the prescribed limit (90/60 mmHg). Symptoms of hypotension may include: blurred or faded vision , dizziness or light-headedness, fainting , fatigue , difficulty concentrating, nausea.
      Mechanism Description
  • Additive hypotensive effects by the combination of Metolazone and Chloral hydrate 
      Mechanism 2 Antihypertensive agent Hypotensive effects
      Key Mechanism Factor 2
Factor Name Hypotensive effects
Factor Description Hypotension is a blood pressure reading below the prescribed limit (90/60 mmHg). Symptoms of hypotension may include: blurred or faded vision , dizziness or light-headedness, fainting , fatigue , difficulty concentrating, nausea.
      Mechanism Description
  • Additive hypotensive effects by the combination of Metolazone and Chloral hydrate 

Recommended Action
      Management Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.

References
1 Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6. [PMID: 2211552]
2 Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139. [PMID: 2005082]
3 Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1. [PMID: 1770159]